Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

Marten A. Lantinga, Hedwig M. A. D’Agnolo, Niek F. Casteleijn, Johan W. Fijter, Esther Meijer, Annemarie L. Messchendorp, Dorien J. M. Peters, Mahdi Salih, Edwin M. Spithoven, Darius Soonawala, Folkert W. Visser, Jack F. M. Wetzels, Robert Zietse, Joost P. H. Drenth and Ron T. Gansevoort ()
Additional contact information
Marten A. Lantinga: Radboud University Medical Center Nijmegen
Hedwig M. A. D’Agnolo: Radboud University Medical Center Nijmegen
Niek F. Casteleijn: University Medical Center Groningen
Johan W. Fijter: Leiden University Medical Center
Esther Meijer: University Medical Center Groningen
Annemarie L. Messchendorp: University Medical Center Groningen
Dorien J. M. Peters: Leiden University Medical Center
Mahdi Salih: Erasmus Medical Center Rotterdam
Edwin M. Spithoven: University Medical Center Groningen
Darius Soonawala: Leiden University Medical Center
Folkert W. Visser: University Medical Center Groningen
Jack F. M. Wetzels: Radboud University Medical Center Nijmegen
Robert Zietse: Erasmus Medical Center Rotterdam
Joost P. H. Drenth: Radboud University Medical Center Nijmegen
Ron T. Gansevoort: University Medical Center Groningen

Drug Safety, 2017, vol. 40, issue 2, No 8, 153-167

Abstract: Abstract Introduction and Aims The DIPAK-1 Study investigates the reno- and hepatoprotective efficacy of the somatostatin analog lanreotide compared with standard care in patients with later stage autosomal dominant polycystic kidney disease (ADPKD). During this trial, we witnessed several episodes of hepatic cyst infection, all during lanreotide treatment. We describe these events and provide a review of the literature. Methods The DIPAK-1 Study is an ongoing investigator-driven, randomized, controlled, open-label multicenter trial. Patients (ADPKD, ages 18–60 years, estimated glomerular filtration rate 30–60 mL/min/1.73 m2) were randomized 1:1 to receive lanreotide 120 mg subcutaneously every 28 days or standard care during 120 weeks. Hepatic cyst infection was diagnosed by local physicians. Results We included 309 ADPKD patients of which seven (median age 53 years [interquartile range: 48–55], 71% female, median estimated glomerular filtration rate 42 mL/min/1.73 m2 [interquartile range: 41–58]) developed eight episodes of hepatic cyst infection during 342 patient-years of lanreotide use (0.23 cases per 10 patient-years). These events were limited to patients receiving lanreotide (p

Keywords: Autosomal Dominant Polycystic Kidney Disease; Lanreotide; Hepatic Cyst; Autosomal Dominant Polycystic Kidney Disease Patient; Cyst Infection (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-016-0486-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:40:y:2017:i:2:d:10.1007_s40264-016-0486-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-016-0486-x

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().